Century Therapeutics (IPSC) Net Margin (2022 - 2025)

Century Therapeutics (IPSC) has 4 years of Net Margin data on file, last reported at 70.13% in Q1 2025.

• Net Margin for Q1 2025 came in at 70.13%, up 335224.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 0.05% (up 190745.0% YoY), and the FY2025 annual result was 0.04%, up 190770.0% from the prior year.
• Net Margin rose to 70.13% in Q1 2025 per IPSC's latest filing, from 843.59% in the prior quarter.
• Over five years, Net Margin peaked at 70.13% in Q1 2025 and troughed at 33627.27% in Q2 2023.
• A 4-year average of 7502.56% and a median of 3545.65% in 2022 frame the typical range for Net Margin.
• The sharpest annual moves came in 2023 and 2024: Net Margin slumped 3140750 bps in 2023, then jumped 2957967 bps in 2024.
• A 4-year view of Net Margin shows it stood at 6080.04% in 2022, then slumped by 142 bps to 14701.87% in 2023, then surged by 94 bps to 843.59% in 2024, then surged by 108 bps to 70.13% in 2025.
• Business Quant data shows IPSC's Net Margin at 70.13% in Q1 2025, 843.59% in Q4 2024, and 3947.66% in Q3 2024.